Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo‐adjuvant chemotherapy. (27th May 2014)

• Record Type: Journal Article
• Authors: Fernanda Amary, M.; Ye, Hongtao; Berisha, Fitim; Khatri, Bhavisha; Forbes, Georgina; Lehovsky, Katie; Frezza, Anna M.; Behjati, Sam; Tarpey, Patrick; Pillay, Nischalan; Campbell, Peter J.; Tirabosco, Roberto; Presneau, Nadège; Strauss, Sandra J.; Flanagan, Adrienne M.
• Is Part Of: Cancer medicine. Volume 3:Number 4(2014:Aug.)
• Page Start: 980
• Page End: 987
• Publication Date: 2014-05-27
• Subjects: 616.994005
• DOI: 10.1002/cam4.268
• Languages: English
• ISSNs: 2045-7634

Abstract

<abstract abstract-type="main" id="cam4268-abs-0001"> <title>Abstract</title> <p>Osteosarcoma, the most common primary bone sarcoma, is a genetically complex disease with no widely accepted biomarker to allow stratification of patients for treatment. After a recent report of one osteosarcoma cell line and one tumor exhibiting <italic>fibroblastic growth factor receptor 1</italic> (<italic>FGFR1</italic>) gene amplification, the aim of this work was to assess the frequency of <italic>FGFR1</italic> amplification in a larger cohort of osteosarcoma and to determine if this biomarker could be used for stratification of patients for treatment. About 352 osteosarcoma samples from 288 patients were analyzed for <italic>FGFR1</italic> amplification by interphase fluorescence in situ hybridization. <italic>FGFR1</italic> amplification was detected in 18.5% of patients whose tumors revealed a poor response to chemotherapy, and no patients whose tumors responded well to therapy harbored this genetic alteration. <italic>FGFR1</italic> amplification is present disproportionately in the rarer histological variants of osteosarcoma. This study provides a rationale for inclusion of patients with osteosarcoma in clinical trials using <italic>FGFR</italic> kinase inhibitors.</p> </abstract>